Evidence map›Paper›PMID 35012478›Full record

ArticleBMC geriatrics2022

Control in the Hospital by Extensive Clinical rules for Unplanned hospitalizations in older Patients (CHECkUP); study design of a multicentre randomized study.

Aimée E M J H Linkens, Vanja Milosevic, Noémi van Nie, Anne Zwietering, Peter W de Leeuw, Marjan van den Akker, Jos M G A Schols, Silvia M A A Evers, Carlota Mestres Gonzalvo, Bjorn Winkens and 7 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC geriatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Polypharmacy and precision medicine.Cambridge prisms. Precision medicine · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Aimée E M J H LinkensDepartment of Internal Medicine, Division of General Internal Medicine, Section Geriatric Medicine, Maastricht University Medical Centre, PO Box 5800, 6202, AZ, Maastricht, The Netherlands. aimee.linkens@mumc.nl.ORCID 0000-0002-9252-7656
Vanja MilosevicClinical Pharmacy, Elkerliek Hospital, Helmond, The Netherlands.
Noémi van NieZuyderland Medical Centre, Heerlen, Limburg, The Netherlands.
Anne ZwieteringDepartment of Internal Medicine, Geriatric Medicine, Zuyderland Medical Centre, Heerlen, The Netherlands.
Peter W de LeeuwDepartment of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
Marjan van den AkkerDepartment of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Jos M G A ScholsDepartment of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Silvia M A A EversDepartment of Family Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Carlota Mestres GonzalvoClinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, Limburg, The Netherlands.
Bjorn WinkensDepartment of Methodology and Statistics, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
Bob P A van de LooDigitalis Rx BV, Amsterdam, The Netherlands.
Louis de WolfGeneral Practitioner, Stein, The Netherlands.
Lucretia PeetersGeneral Pharmacist, Heerlen, The Netherlands.
Monique de ReeGeneral Pharmacist, Susteren, The Netherlands.
Bart SpaetgensDepartment of Internal Medicine, Division of General Internal Medicine, Section Geriatric Medicine, Maastricht University Medical Centre, PO Box 5800, 6202, AZ, Maastricht, The Netherlands.
Kim P G M HurkensDepartment of Internal Medicine, Geriatric Medicine, Zuyderland Medical Centre, Heerlen, The Netherlands.
Hugo M van der KuyDepartment of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, 3015, GD, Rotterdam, The Netherlands.
Maastricht University Medical Centre · NLMaastricht University · NLZuyderland Medisch Centrum · NLElkerliek Ziekenhuis · NLErasmus MC · NLGeneral Practitioners Research Institute · NLGoethe University Frankfurt · DERoyal Dutch Pharmacists Association · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to ageing of the population the incidence of multimorbidity and polypharmacy is rising. Polypharmacy is a risk factor for medication-related (re)admission and therefore places a significant burden on the healthcare system. The reported incidence of medication-related (re)admissions varies widely due to the lack of a clear definition. Some medications are known to increase the risk for medication-related admission and are therefore published in the triggerlist of the Dutch guideline for Polypharmacy in older patients. Different interventions to support medication optimization have been studied to reduce medication-related (re)admissions. However, the optimal template of medication optimization is still unknown, which contributes to the large heterogeneity of their effect on hospital readmissions. Therefore, we implemented a clinical decision support system (CDSS) to optimize medication lists and investigate whether continuous use of a CDSS reduces the number of hospital readmissions in older patients, who previously have had an unplanned probably medication-related hospitalization.

methodsThe CHECkUP study is a multicentre randomized study in older (≥60 years) patients with an unplanned hospitalization, polypharmacy (≥5 medications) and using at least two medications from the triggerlist, from Zuyderland Medical Centre and Maastricht University Medical Centre+ in the Netherlands. Patients will be randomized. The intervention consists of continuous (weekly) use of a CDSS, which generates a Medication Optimization Profile, which will be sent to the patient's general practitioner and pharmacist. The control group will receive standard care. The primary outcome is hospital readmission within 1 year after study inclusion. Secondary outcomes are one-year mortality, number of emergency department visits, nursing home admissions, time to hospital readmissions and we will evaluate the quality of life and socio-economic status. DISCUSSION: This study is expected to add evidence on the knowledge of medication optimization and whether use of a continuous CDSS ameliorates the risk of adverse outcomes in older patients, already at an increased risk of medication-related (re)admission. To our knowledge, this is the first large study, providing one-year follow-up data and reporting not only on quality of care indicators, but also on quality-of-life.

trial registrationThe trial was registered in the Netherlands Trial Register on October 14, 2018, identifier: NL7449 (NTR7691). https://www.trialregister.nl/trial/7449 .

Indexed as

HospitalizationQuality of LifeAgedHospitalsHumansMulticenter Studies as TopicMultimorbidityPolypharmacyRandomized Controlled Trials as TopicClinical decision support systemMedication optimisationOlder patientsPolypharmacyReadmissions

Identifiers

PMID35012478
PMCPMC8744034
OpenAlexW4205224595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.